196 related articles for article (PubMed ID: 9186171)
21. [Does hypothyroidism predispose muscular toxicity of fibrates?].
Tregouet B
Rev Med Interne; 1991; 12(2):159. PubMed ID: 1853004
[No Abstract] [Full Text] [Related]
22. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
Harvengt C
Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
[No Abstract] [Full Text] [Related]
23. Creatinine rise after fibrate therapy in renal graft recipients.
Devuyst O; Goffin E; Pirson Y; van Ypersele de Strihou C
Lancet; 1993 Mar; 341(8848):840. PubMed ID: 8096050
[No Abstract] [Full Text] [Related]
24. Rhabdomyolysis and lipid-lowering drugs.
Tenenbaum A; Fisman EZ; Motro M
JAMA; 2005 Mar; 293(12):1448; author reply 1448-9. PubMed ID: 15784863
[No Abstract] [Full Text] [Related]
25. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia.
Mastroianni CM; d'Ettorre G; Forcina G; Lichtner M; Corpolongo A; Coletta S; Vullo V
AIDS; 2001 Apr; 15(6):820-1. PubMed ID: 11371708
[No Abstract] [Full Text] [Related]
26. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
[No Abstract] [Full Text] [Related]
27. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment.
Górriz JL; Sancho A; Alcoy E; García-Ramos JL; Pallardó LM
Nephrol Dial Transplant; 1995 Dec; 10(12):2371-2. PubMed ID: 8808248
[No Abstract] [Full Text] [Related]
28. [Rhabdomyolysis complicated with acute renal insufficiency in a patient treated with gemfibrozil and cerivastatin].
Vascónez Espinosa F; Gómez Rodríguez N; Martín Joven A; Posada García FJ
Rev Clin Esp; 2001 Apr; 201(4):228-9. PubMed ID: 11447919
[No Abstract] [Full Text] [Related]
29. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
Baglin A; Lasserre N; Prinseau J; Lebas M
Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
[No Abstract] [Full Text] [Related]
30. [Rhabdomyolysis with acute renal failure due to bezafibrate].
Heidemann H; Bock KD
Klin Wochenschr; 1981 Apr; 59(8):413-4. PubMed ID: 7289450
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Turpin G; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
[TBL] [Abstract][Full Text] [Related]
32. Lipid profiles on fibric-acid derivatives.
Capps NE
Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
[No Abstract] [Full Text] [Related]
33. Abnormal lipid profiles on fibrate derivatives.
McLeod AJ; Warren RJ; Armitage M
Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
[No Abstract] [Full Text] [Related]
34. Ibuprofen and acute renal failure in a toddler.
Moghal NE; Hegde S; Eastham KM
Arch Dis Child; 2004 Mar; 89(3):276-7. PubMed ID: 14977711
[No Abstract] [Full Text] [Related]
35. Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
Legras B; Clerc C; Ruelland A; Doualin G; Fertil V; Cloarec L
Clin Chem; 1990 Mar; 36(3):580-1. PubMed ID: 2107044
[No Abstract] [Full Text] [Related]
36. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
[TBL] [Abstract][Full Text] [Related]
37. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Oldemeyer JB; Lund RJ; Koch M; Meares AJ; Dunlay R
Cardiology; 2000; 94(2):127-8. PubMed ID: 11173785
[TBL] [Abstract][Full Text] [Related]
38. Perioperative acute renal failure associated with preoperative intake of ibuprofen.
Sivarajan M; Wasse L
Anesthesiology; 1997 Jun; 86(6):1390-2. PubMed ID: 9197311
[No Abstract] [Full Text] [Related]
39. Effects of various fibrates on serum alkaline phosphatase activity.
Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
[No Abstract] [Full Text] [Related]
40. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
